Form 8-K - Current report:
SEC Accession No. 0001193125-22-246030
Filing Date
2022-09-16
Accepted
2022-09-16 07:36:04
Documents
16
Period of Report
2022-09-16
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d362957d8k.htm   iXBRL 8-K 45059
2 EX-99.1 d362957dex991.htm EX-99.1 39488
3 EX-99.2 d362957dex992.htm EX-99.2 27880
7 GRAPHIC g362957dsp13.jpg GRAPHIC 16696
8 GRAPHIC g362957g43m92.jpg GRAPHIC 16327
  Complete submission text file 0001193125-22-246030.txt   307583

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ntla-20220916.xsd EX-101.SCH 2854
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20220916_lab.xml EX-101.LAB 17995
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20220916_pre.xml EX-101.PRE 11260
10 EXTRACTED XBRL INSTANCE DOCUMENT d362957d8k_htm.xml XML 3344
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 221246974
SIC: 2835 In Vitro & In Vivo Diagnostic Substances